DelveInsight’s, “Vascular Dementia Pipeline Insight, 2023,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Vascular Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Vascular Dementia Pipeline

 

• Over 12+ Vascular Dementia Companies are evaluating 12+ Vascular Dementia pipeline therapies in various stages of development, and their anticipated acceptance in the Vascular Dementia market would significantly increase market revenue.

 

• The leading Vascular Dementia Companies include Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, and others

 

• Promising Vascular Dementia Pipeline Therapies include donepezil hydrochloride (Aricept), Cerebrolysin, Prospecta, Rivastigmine, SaiLuoTong capsule, Akatinol Memantine 20 mg, Cilostazol, Aspirin, galantamine hydrobromide, and others

 

• The Vascular Dementia companies and academics are working to assess challenges and seek opportunities that could influence Vascular Dementia R&D. The Vascular Dementia therapies under development are focused on novel approaches to treat/improve Vascular Dementia.

 

To explore more information on the latest breakthroughs in the Vascular Dementia Pipeline treatment landscape of the report, click here @ Vascular Dementia Pipeline Outlook

 

Vascular Dementia Overview

Vascular dementia (VaD) is one of the most common causes of dementia after Alzheimer’s disease, causing around 15% of cases. Vascular dementia may result not only from large-vessel strokes (multi-infarct dementia) but also from ischemic lesions caused by small-vessel pathology, including lacunar strokes and incomplete white matter ischemia (subcortical ischemic vascular dementia), as well as from hypoperfusion caused by heart disease or circulatory disturbances.

 

Recent Developmental Activities in the Vascular Dementia Treatment Landscape

 

• NBP has antioxidant activities and may protect against oxidative/nitrosative stress, mitochondrial impairment and apoptosis. The drug is currently in Phase III stage of development for the treatment of patients with Vascular Dementia.

 

For further information, refer to the detailed Vascular Dementia Unmet Needs, Vascular Dementia Market Drivers, and Vascular Dementia Market Barriers, click here for Vascular Dementia Ongoing Clinical Trial Analysis

 

Vascular Dementia Emerging Drugs Profile

 

Akatinol Memantine: Merz Pharma

Akatinol Memantine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. Memantine is marketed for the treatment of moderate to severe Alzheimer’s disease. Memantine works by blocking NMDA receptors, to which the neurotransmitter glutamate normally attaches. Neurotransmitters are chemicals in the nervous system that allow nerve cells to communicate with one another and overstimulation of the NMDA receptors can result in cell damage or death. The drug is in Phase III clinical development for the treatment of Vascular Dementia.

 

Butylphthalide soft capsules: CSPC Ouyi Pharmaceutical

Butylphthalide (NBP) is a compound found in Chinese celery seed extracts that can improve cognitive functions and may decrease Amyloid-beta levels in Alzheimer′s disease.

 

SaiLuoTong: Shineway Pharmaceutical

Sailuotong (SLT) capsule is a standardized three-herb preparation composed of ginseng, ginkgo, and saffron being evaluated for the treatment of vascular dementia in Phase III stage of development.

 

Vascular Dementia Pipeline Therapeutics Assessment

There are approx. 12+ key companies which are developing the therapies for Vascular Dementia. The companies which have their Vascular Dementia drug candidates in the most advanced stage, i.e. phase III include, Merz Pharma.

 

Request a sample and discover the recent advances in Vascular Dementia Ongoing Clinical Trial Analysis and Medications, click here @ Vascular Dementia Treatment Landscape

 

Scope of the Vascular Dementia Pipeline Report

 

• Coverage- Global

 

• Vascular Dementia Companies- Merz Pharma, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, Shineway Pharmaceutical, Materia Medica Holding, Acadia Pharmaceuticals, CSPC Ouyi Pharmaceutical, Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company, Charsire Pharmaceutical, Cyclerion therapeutics, AriBio, DiaMedica Therapeutics, Suven Life Sciences, Guangzhou Magpie Pharmaceuticals, Resverlogix, ProNeurogen Therapeutics, and others

 

• Vascular Dementia Pipeline Therapies- donepezil hydrochloride (Aricept), Cerebrolysin, Prospecta, Rivastigmine, SaiLuoTong capsule, Akatinol Memantine 20 mg, Cilostazol, Aspirin, galantamine hydrobromide, and others.

 

• Vascular Dementia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Vascular Dementia Market Drivers and Vascular Dementia Market Barriers, click here @ Vascular Dementia Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Vascular Dementia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Vascular Dementia – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Vascular Dementia Collaboration Deals
9. Late Stage Products (Phase III)
10. Akatinol Memantine: Merz Pharma
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. CY6463: Cyclerion therapeutics
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. AR1001: AriBio
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Vascular Dementia Key Companies
20. Vascular Dementia Key Products
21. Vascular Dementia- Unmet Needs
22. Vascular Dementia- Market Drivers and Barriers
23. Vascular Dementia- Future Perspectives and Conclusion
24. Vascular Dementia Analyst Views
25. Vascular Dementia Key Companies
26. Appendix

 

Got Queries? Find out the related information on Vascular Dementia Mergers and acquisitions, Vascular Dementia Licensing Activities @ Vascular Dementia Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/